OPEN-LABEL, MULTICENTRE, PHASE IB DOSE ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRATUZUMAB +/- FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BRESAST CÁNCER PROGRESSED TO ANTI-HER2 BASED THERAPY
2017-004631-36HER2 POSITIVO CON MUTACION PIK3CAFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
